Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Total Non-Current Liabilities (2016 - 2024)

BioCorRx's Total Non-Current Liabilities history spans 10 years, with the latest figure at $12.7 million for Q4 2024.

  • For Q4 2024, Total Non-Current Liabilities rose 23.85% year-over-year to $12.7 million; the TTM value through Dec 2024 reached $12.7 million, up 23.85%, while the annual FY2024 figure was $12.7 million, 23.85% up from the prior year.
  • Total Non-Current Liabilities for Q4 2024 was $12.7 million at BioCorRx, up from $12.6 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $12.7 million in Q4 2024 and bottomed at $9.0 million in Q4 2022.
  • The 3-year median for Total Non-Current Liabilities is $11.3 million (2024), against an average of $11.2 million.
  • The largest annual shift saw Total Non-Current Liabilities grew 14.71% in 2023 before it grew 23.85% in 2024.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $9.0 million in 2022, then increased by 14.71% to $10.3 million in 2023, then increased by 23.85% to $12.7 million in 2024.
  • Per Business Quant, the three most recent readings for BICX's Total Non-Current Liabilities are $12.7 million (Q4 2024), $12.6 million (Q3 2024), and $11.5 million (Q2 2024).